Novonesis AS (NVZMY)
55.03
+0.57
(+1.05%)
USD |
OTCM |
Apr 19, 15:59
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 25.55B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 2.84% |
| Valuation | |
| PE Ratio | 34.84 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 5.887 |
| Price to Book Value | 12.31 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.2885 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5268 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 51.95% |
Profile
| Novonesis AS formerly Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company is the world leader in industrial enzymes and microbial solutions, with a near-50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, working across more than 30 research and development and application centers and 23 manufacturing sites. |
| URL | https://www.novozymes.com |
| Investor Relations URL | https://investors.novozymes.com/ |
| HQ State/Province | N/A |
| Sector | Materials |
| Industry | Chemicals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | May. 03, 2024 |
| Last Earnings Release | Feb. 01, 2024 |
| Next Ex-Dividend Date | May. 01, 2024 |
| Last Ex-Dividend Date | Oct. 20, 2023 |
Ratings
Profile
| Novonesis AS formerly Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company is the world leader in industrial enzymes and microbial solutions, with a near-50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, working across more than 30 research and development and application centers and 23 manufacturing sites. |
| URL | https://www.novozymes.com |
| Investor Relations URL | https://investors.novozymes.com/ |
| HQ State/Province | N/A |
| Sector | Materials |
| Industry | Chemicals |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | May. 03, 2024 |
| Last Earnings Release | Feb. 01, 2024 |
| Next Ex-Dividend Date | May. 01, 2024 |
| Last Ex-Dividend Date | Oct. 20, 2023 |